Medical Condition News

RSS

Study finds combined treatments safe and effective for severe acute pancreatitis

The use of combined treatments for severe acute pancreatitis is safe and effective in managing the disease, resulting in shorter hospitalizations and fewer radiological procedures than standard therapy, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. In a related study, doctors found that patients with infected pancreatic necrosis were able to avoid surgery through primary conservative treatment, which is in-patient medical treatment.

7 Jan 2011

Single cellular crisis shatters chromosomes in cancer causation

Remarkable new research overthrows the conventional view that cancer always develops in a steady, stepwise progression. It shows that in some cancers, the genome can be shattered into hundreds of fragments in a single cellular catastrophe, wreaking mutation on a massive scale.

7 Jan 2011

ASBP raises concern over FDA recommendations to lower BMI requirements for lap-band surgery

The American Society of Bariatric Physicians (ASBP) is concerned that the FDA advisory panel recommended lowering the BMI requirement for lap-band surgery, while the FDA recently denied two new obesity medications. Bariatric surgery is drastic and expensive and carries higher morbidity and mortality risks than lifestyle interventions or medication. Patients who could have otherwise lost weight in a non-surgical medical bariatric program may now be encouraged to skip medical therapy and jump directly to surgery.

7 Jan 2011

Chromosome shattering seen in two to three percent of all cancers

Most of the time cancer seems to creep up gradually over time; cells become premalignant, then increasingly abnormal before they become cancerous. But sometimes cancers seem to pop up as if out of nowhere. Now, researchers reporting in the January 7th issue of the journal Cell, a Cell Press publication, have new evidence to explain how that can happen.

7 Jan 2011

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

BG Medicine, Inc. announced today that it has entered into an agreement with Siemens Healthcare Diagnostics Inc., a division of Siemens Healthcare, one of the world's largest suppliers of clinical diagnostics to the healthcare industry, for the development and commercialization of a galectin-3 test for Siemens' automated immunoassay platforms for clinical laboratories.

7 Jan 2011

Plexxikon, Genentech enter PLX4032 co-promotion agreement

Plexxikon, Inc., announced today that it has signed an agreement with Genentech to co-promote PLX4032 (RG7204) in the United States. PLX4032, an oral, novel kinase inhibitor that targets the oncogenic BRAF mutation, is being tested in late-stage clinical trials for the treatment of metastatic melanoma.

7 Jan 2011

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Cell Medica, a leading cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, is pleased to announce an exclusive license agreement and research collaboration with the Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine (Houston, Texas), for the commercialization of an innovative cell-based treatment for cancers associated with the oncogenic Epstein Barr virus (EBV).

7 Jan 2011

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.

7 Jan 2011

Spirogen, Genentech enter multi-year ADC research collaboration and license agreement

Spirogen Ltd. a leading oncology-focused company developing DNA sequence targeted agents, announced a multi-year research collaboration and license agreement with Genentech, a member of the Roche Group.

7 Jan 2011

Study examines link between media consumption, eating disorders among adolescent girls in Fiji

For parents wanting to reduce the negative influence of TV on their children, the first step is normally to switch off the television set. But a new study suggests that might not be enough. It turns out indirect media exposure, i.e., having friends who watch a lot of TV, might be even more damaging to a teenager's body image.

7 Jan 2011

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.

7 Jan 2011

Biomarker study yields diagnostic blood test candidate for detection of Alzheimer's disease

OPKO Health, Inc. today announced the publication of a biomarker study yielding its diagnostic blood test candidate for the detection of Alzheimer's disease.

7 Jan 2011

Cells that give rise to neurons maintain high levels of ROS

For years, the majority of research on reactive oxygen species (ROS) - ions or very small molecules that include free radicals - has focused on how they damage cell structure and their potential link to stroke, cardiovascular disease and other illnesses.

7 Jan 2011

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

TGen Drug Development (TD2) and Oncoholdings Inc. announced today a partnership agreement that could lead to the prompt development of new anti-cancer agents.

7 Jan 2011

HRG protein inhibits tumor growth and metastasis: Study

Most cancer tissues are invaded by inflammatory cells that either stimulate or inhibit the growth of the tumor, depending on what immune cells are involved. Now a Swedish-Belgian research team has shown that a protein that naturally occurs in the body, HRG, inhibits tumor growth and metastasis into secondary organs by activating specific immune cells.

7 Jan 2011

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc., and RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, today announced that they have obtained positive early research data from their collaboration to explore the use of RXi's RNAi technology to develop proprietary vaccine formulations for active immunotherapy.

7 Jan 2011

Driving convertible cars with top open may increase risk of noise-induced hearing loss

Driving convertible cars with the top open at speeds exceeding 88.5 kilometres per hour may put drivers at increased risk of noise-induced hearing loss, according to new research published in The Journal of Laryngology and Otology, by Cambridge University Press on behalf of JLO Ltd from the Saint Louis University School of Medicine, Missouri and The Ear Institute of Texas, San Antonio.

7 Jan 2011

Scientists perform surgery on single cell to extract and examine mitochondria

Medical researchers who crave a means of exploring the genetic culprits behind a host of neuromuscular disorders may have just had their wish granted by a team working at the National Institute of Standards and Technology, where scientists have performed surgery on single cells to extract and examine their mitochondria.

7 Jan 2011

Regular blood test shows pre-diabetes risk factors, reduces treatment costs

A simpler form of testing individuals with risk factors for diabetes could improve diabetes prevention efforts by substantially increasing the number of individuals who complete testing and learn whether or not they are likely to develop diabetes.

7 Jan 2011

Seattle Genetics enters ADC collaboration agreement with Pfizer

Seattle Genetics, announced today that it has entered into a collaboration agreement with Pfizer under which Pfizer will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.

7 Jan 2011

Medical Condition News

Study finds combined treatments safe and effective for severe acute pancreatitis

Single cellular crisis shatters chromosomes in cancer causation

ASBP raises concern over FDA recommendations to lower BMI requirements for lap-band surgery

Chromosome shattering seen in two to three percent of all cancers

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

Plexxikon, Genentech enter PLX4032 co-promotion agreement

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Spirogen, Genentech enter multi-year ADC research collaboration and license agreement

Study examines link between media consumption, eating disorders among adolescent girls in Fiji

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

Biomarker study yields diagnostic blood test candidate for detection of Alzheimer's disease

Cells that give rise to neurons maintain high levels of ROS

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

HRG protein inhibits tumor growth and metastasis: Study

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Driving convertible cars with top open may increase risk of noise-induced hearing loss

Scientists perform surgery on single cell to extract and examine mitochondria

Regular blood test shows pre-diabetes risk factors, reduces treatment costs

Seattle Genetics enters ADC collaboration agreement with Pfizer

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Latest News